Publications by authors named "S Lentzsch"
Primary systemic amyloidosis, or light chain (AL) amyloidosis, is a rare lymphoproliferative disorder in which aberrant light-chain immunoglobulins secreted into the bloodstream aggregate into fibrils and deposit into tissues, causing widespread organ damage and, if not treated, death. This review provides a comprehensive summary of the pathophysiology and manifestations of AL amyloidosis; standard-of-care diagnostic approach; typical treatment regimens; and areas of active investigation.
View Article and Find Full Text PDFThe Undetermined Significance of Screening for Monoclonal Gammopathy of Undetermined Significance.
Cancer Epidemiol Biomarkers Prev
December 2024
The identification of premalignant lesions in solid tumors such as colorectal and cervical cancer has led to the development of highly effective population-wide screening programs for these malignancies. Although precursor clinical states are not well-established for most hematologic malignancies, multiple myeloma is a notable exception. Virtually all patients with multiple myeloma first develop monoclonal gammopathy of undetermined significance (MGUS), an asymptomatic but easily detectable condition.
View Article and Find Full Text PDFArticle Synopsis
- *In a study of 27 patients, a specific genetic abnormality (translocation 11;14) was found in 45% of cases, affecting patient outcomes, including light-chain ratios and renal function.
- *Progression to end stage renal disease (ESRD) was significantly linked to low eGFR and high protein levels at diagnosis, suggesting the need for targeted therapies like BCL2 inhibitors for more effective management.
Article Synopsis
- - The study analyzed the effects of cytogenetic abnormalities in 283 AL amyloidosis patients treated with daratumumab-based therapies, focusing on abnormalities like t(11;14), deletion(13q), and gain/amp(1q).
- - Among various subgroups, only +1q showed a significant lower rate of very good partial response and was linked to worse hematologic event-free survival, while t(11;14) did not negatively impact overall survival.
- - The findings suggest that patients with the +1q abnormality may benefit from targeted clinical trials with novel immunotherapies to improve their treatment outcomes.
Article Synopsis
- The Glasgow prognostic score (GPS) and CAR-HEMATOTOX (CAR-HT) score help identify multiple myeloma (MM) patients at risk for immune-related side effects and early death during cellular immunotherapy.
- A study involving 126 MM patients treated with T-cell redirecting bispecific antibodies (bsAb) assessed the impact of these scores on patient outcomes.
- While 19% of patients were deemed high risk according to GPS, they did not experience worse outcomes, but those classified as high risk by CAR-HT faced more infections and had lower survival rates, indicating the need for better infection management.